Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder
- 13 November 2007
- journal article
- Published by Wiley in BJU International
- Vol. 101 (8), 969-972
- https://doi.org/10.1111/j.1464-410x.2007.07335.x
Abstract
To evaluate the presentation, location and overall survival of pelvic recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) of the bladder. We reviewed a consecutive series of 130 patients who had a limited bilateral pelvic lymph node dissection (PLND) and RC between 1987 and 2000, and who later developed pelvic recurrence. All patients were staged N0M0 before RC and no patient received neoadjuvant radio/chemotherapy. The boundaries of the limited PLND were the pelvic side-wall between the genitofemoral and obturator nerves, and the bifurcation of iliac vessels to the circumflex iliac vein. Pelvic recurrence was defined as a radiographic soft-tissue density of > or = 2 cm below the bifurcation of the aorta. Kaplan-Meier and Cox proportional hazards analyses were used to determine if imaging or symptomatic presentation, age, pT stage, and pN status were predictive of overall survival. The median (range) time from RC to pelvic recurrence was 7.3 (1.2-55.4) months. No patients had concomitant distant metastasis. Of the patients, 61.5% were diagnosed with pelvic recurrence because of symptoms, and 38.5% by surveillance computed tomography (CT). Of the 130 patients, 128 died, with a median survival from the time of pelvic recurrence of 4.9 (0.1-129.3) months. The median overall survival time for pelvic recurrence diagnosed with CT was 21.6 months, vs 10.6 months for symptomatic presentations (P < 0.001). In the uni- and multivariate models, type of presentation (CT vs symptomatic) and pT stage were predictors of overall survival, while age and pN status were not. The prognosis of patients with pelvic recurrence after RC for TCC is poor even with subsequent therapy, emphasizing the need for optimum local control at the time of initial treatment.Keywords
This publication has 12 references indexed in Scilit:
- Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissectionBJU International, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant TherapyJournal of Clinical Oncology, 2003
- ILEAL NEOBLADDER AND LOCAL RECURRENCE OF BLADDER CANCER: PATTERNS OF FAILURE AND IMPACT ON FUNCTION IN MENJournal of Urology, 1999
- PRESENTATION, METHODS OF DIAGNOSIS AND THERAPY FOR PELVIC RECURRENCE FOLLOWING RADICAL CYSTECTOMY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDERJournal of Urology, 1998
- Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.Journal of Clinical Oncology, 1997
- Paclitaxel, Cisplatin and Methotrexate Combination Chemotherapy is Active in the Treatment of Refractory Urothelial MalignanciesJournal of Urology, 1995
- Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy aloneInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Pelvic Recurrence after Radical Cystectomy without Preoperative RadiationJournal of Urology, 1988
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988